ImmunoPrecise Regains Compliance with Nasdaq Minimum Bid Price Requirement
We're building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond.
The notice, dated July 11, 2025, stated that for the 10 consecutive business days from June 26, 2025, through July 10, 2025, the closing bid price of the Company's common shares was at or above $1.00 per share. As a result, ImmunoPrecise has satisfied the requirements for continued listing on the Nasdaq Capital Market, and the matter is now closed.
'This compliance milestone reflects the growing recognition of our evolution into a platform company built around bio-native AI,' said Dr. Jennifer Bath, CEO of ImmunoPrecise. 'We're building the digital infrastructure that connects biological complexity with real-world impact - enabling new possibilities in therapeutic development and beyond. The recent momentum in our share price is a strong signal of support for that vision.'
Through its proprietary LENS ai™ platform powered by HYFT ® technology, ImmunoPrecise is reimagining how biological data can be modeled and deployed at scale. The LENS ai platform is transforming therapeutic discovery from a decades-long process to rapid, precision-guided development by systematically identifying the most promising therapeutic pathways through integration of sequence, structure, literature and functional data across the entire biosphere.
Our integrated framework enables unprecedented zero-shot discovery scenarios where LENS ai predicts therapeutic interactions for completely novel targets, demonstrated through recent validation across 17 previously unseen antibody-protein complexes, achieving near-crystallography precision without prior training data. This unique bio-native AI approach captures functional meaning rather than structural patterns, enabling new capabilities across R&D from drug and vaccine discovery to systems biology and positioning IPA at the frontier of TechBio innovation.
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) is advancing Bio-Native™ AI at the intersection of biology and computation. The Company's LENSai™ and HYFT ® platforms enable large-scale reasoning across sequence, structure, function, and scientific literature, powering next-generation workflows across drug discovery, diagnostics, vaccine design, and molecular systems biology.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of applicable United States and Canadian securities laws. Forward-looking statements are often identified by words such as 'expects,' 'intends,' 'plans,' 'anticipates,' 'believes,' or similar expressions, or by statements that certain actions, events, or results 'may,' 'will,' 'could,' or 'might' occur or be achieved. These statements include, but are not limited to, statements regarding the Company's strategic direction, the Company's future growth, its ability to execute on its scientific, commercial, and capital markets initiatives, and the continued evolution of its leadership and business strategy.
Forward-looking statements are based on management's current expectations, assumptions, and projections about future events. Actual results may differ materially from those expressed or implied due to a variety of factors, many of which are beyond the Company's control. These factors include, but are not limited to, changes in board or executive leadership; shifts in strategic priorities; scientific or operational challenges; evolving market and economic conditions; changes in regulatory environments; the pace of innovation in AI and biotechnology; and other risks inherent to the Company's industry and business model.
Forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied herein. Additional information regarding risks and uncertainties is included in the Company's Annual Report on Form 20-F, as amended, for the fiscal year ended April 30, 2024, available on the Company's SEDAR+ profile at www.sedarplus.ca and EDGAR profile at www.sec.gov/edgar. Should any of these risks materialize, actual results could vary significantly from those currently anticipated.
Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
33 minutes ago
- Yahoo
Discovering Undiscovered Gems in the US Market August 2025
As the U.S. stock market navigates through a period of mixed performance with the Dow Jones Industrial Average reaching new highs while the S&P 500 and Nasdaq face declines, investors are keenly observing potential shifts in Federal Reserve policies that could impact future market dynamics. In this environment, identifying stocks with strong fundamentals and growth potential becomes crucial, especially as major indices fluctuate and economic indicators remain uncertain. Top 10 Undiscovered Gems With Strong Fundamentals In The United States Name Debt To Equity Revenue Growth Earnings Growth Health Rating Southern Michigan Bancorp 117.38% 8.87% 4.89% ★★★★★★ Oakworth Capital 87.50% 15.82% 9.79% ★★★★★★ ASA Gold and Precious Metals NA 12.79% -0.59% ★★★★★★ Sound Financial Bancorp 34.70% 2.11% -11.08% ★★★★★★ Metalpha Technology Holding NA 75.66% 28.60% ★★★★★★ First Northern Community Bancorp NA 8.05% 12.27% ★★★★★★ Senstar Technologies NA -20.82% 14.32% ★★★★★★ Valhi 44.30% 1.10% -1.40% ★★★★★☆ Pure Cycle 5.02% 4.35% -2.25% ★★★★★☆ Rich Sparkle Holdings 26.73% -6.13% 1.75% ★★★★★☆ Click here to see the full list of 286 stocks from our US Undiscovered Gems With Strong Fundamentals screener. Let's review some notable picks from our screened stocks. Carter Bankshares Simply Wall St Value Rating: ★★★★☆☆ Overview: Carter Bankshares, Inc. is the bank holding company for Carter Bank & Trust, offering a range of retail and commercial banking products and insurance services in the United States, with a market capitalization of $414.86 million. Operations: Carter Bankshares generates revenue primarily from its banking segment, totaling $153.12 million. Carter Bankshares, with assets totaling US$4.8 billion and equity of US$405.6 million, has been making waves recently. The company reported a significant earnings growth of 152.5% over the past year, outperforming the industry average of 12.5%. Despite this impressive performance, it grapples with a high level of bad loans at 6.7%, coupled with an insufficient allowance for bad loans at 28%. Recently added to multiple Russell indexes and completing a share buyback worth US$10.41 million for 171,899 shares, CARE seems poised for continued attention in investment circles due to its strong earnings momentum and strategic moves. Delve into the full analysis health report here for a deeper understanding of Carter Bankshares. Learn about Carter Bankshares' historical performance. Northrim BanCorp Simply Wall St Value Rating: ★★★★★★ Overview: Northrim BanCorp, Inc. is the bank holding company for Northrim Bank, offering commercial banking products and services to businesses and professional individuals, with a market cap of $476.66 million. Operations: Northrim BanCorp generates revenue primarily through its Community Banking segment with $121.89 million, followed by Home Mortgage Lending at $35.57 million and Specialty Finance contributing $6.39 million. Northrim BanCorp, with assets totaling US$3.2 billion and equity of US$290.2 million, stands out for its robust financial health. The company boasts total deposits of US$2.8 billion against loans of US$2.2 billion, indicating a solid funding base primarily from customer deposits—considered low risk compared to external borrowing. Its allowance for bad loans is sufficient at 190%, covering non-performing loans which are just 0.5% of total loans, well within acceptable limits. Recent earnings growth was impressive at 39%, far surpassing the industry average of 12%. Northrim's inclusion in multiple Russell indices highlights its recognition as a promising player in the market landscape. Get an in-depth perspective on Northrim BanCorp's performance by reading our health report here. Examine Northrim BanCorp's past performance report to understand how it has performed in the past. Shore Bancshares Simply Wall St Value Rating: ★★★★★★ Overview: Shore Bancshares, Inc. functions as a bank holding company for Shore United Bank, N.A., with a market capitalization of $525.66 million. Operations: Shore Bancshares generates revenue primarily from its community banking segment, which reported $208.21 million. Shore Bancshares, with total assets of US$6.0 billion and equity of US$565.2 million, presents a robust financial profile. Its net interest margin stands at 3.1%, supported by total deposits of US$5.3 billion and loans amounting to US$4.8 billion. The bank maintains a sufficient allowance for bad loans at 344% coverage, with non-performing loans at just 0.3%. Trading at a price-to-earnings ratio of 9.9x, it offers good value compared to the broader market's 18.8x average, while its earnings growth last year outpaced the industry significantly by reaching an impressive 166%. Dive into the specifics of Shore Bancshares here with our thorough health report. Gain insights into Shore Bancshares' past trends and performance with our Past report. Key Takeaways Take a closer look at our US Undiscovered Gems With Strong Fundamentals list of 286 companies by clicking here. Already own these companies? Bring clarity to your investment decisions by linking up your portfolio with Simply Wall St, where you can monitor all the vital signs of your stocks effortlessly. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Seeking Other Investments? Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. Find companies with promising cash flow potential yet trading below their fair value. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include CARE NRIM and SHBI. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
44 minutes ago
- Yahoo
Viking Therapeutics stock falls 37% on high dropout rate in obesity trial
-- Viking Therapeutics (NASDAQ:VKTX) stock plunged as much as 37% Tuesday after revealing results from its Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment, while Eli Lilly (NYSE:LLY) shares gained 1.5% as analysts pointed to competitive advantages. The trial demonstrated that Viking's oral tablet formulation of VK2735, a dual GLP-1 and GIP receptor agonist, met its primary endpoint with patients losing up to 12.2% of body weight after 13 weeks compared to 1.3% for placebo. Despite the weight loss efficacy, the 28% treatment discontinuation rate among patients receiving VK2735 versus 18% for placebo raised significant concerns among investors and analysts. Mizuho analyst Jared Holz highlighted competitive disadvantages compared to Eli Lilly's offerings: "Data look inferior to LLY on almost all metrics and the thing to consider here is that patients discontinued at such a high rate over 13-weeks vs. LLY in the mid 20% range --- but over 72-weeks; A much longer trial, and therefor LLY looks far better head-to-head. This probably shutters hope for VKTX a bigtime player in the oral obesity market over the near to medium term." JPMorgan (NYSE:JPM) analyst Hardik Parikh offered a more balanced view, noting, "In 13 weeks, the three highest-dosing arms of 60/90/120mg showed avg pbo-adj weight loss of ~7.5%, 10%, 11%, which we think is very strong compared with other orals in development. Tolerability overall was manageable, but it was worse than we expected based on the ph1 performance." Parikh added that while the adverse event profile wasn't as clean as in Phase 1 trials, "we still think oral vk-2735 offers strong efficacy with a manageable tolerability profile." Viking reported that 99% of gastrointestinal-related adverse events were mild or moderate. The company also highlighted an exploratory maintenance dosing arm showing weight loss could be maintained at lower doses. The major adverse events included vomiting rates of 20-35% in the three highest dose arms compared to about 10% for placebo, and nausea rates of approximately 58% for patients on treatment versus 48% for placebo. Related articles Viking Therapeutics stock falls 37% on high dropout rate in obesity trial Tesla robotaxi trial impresses, pricing power clear: William Blair Palo Alto Networks gains after strong earnings and Bank of America upgrade
Yahoo
an hour ago
- Yahoo
Bitcoin Treasury KindlyMD Stock Dives Following $679 Million BTC Buy
Bitcoin treasury KindlyMD has added $679 million in BTC to its holdings, the company said Tuesday—though the firm's stock has taken a plunge following the announcement. The Nasdaq-listed company said that it had bought 5,743.91 BTC via its wholly owned subsidiary, Nakamoto Holdings, Inc, for an average price of about $118,205 per coin. Bitcoin was recently trading for $113,200, down 2.4% over a 24-hour period and by more than 5% over the past week after hitting a new all-time high mark above $124,000 last week. "This acquisition reinforces our conviction in Bitcoin as the ultimate reserve asset for corporations and institutions alike," David Bailey, the company's CEO said. Bitcoin Treasury KindlyMD Closes $200 Million Raise to Buy More BTC KindlyMD's stock—which trades under the ticker NAKA—was down by more than 13% Tuesday to a price of $10.41. The firm, which focuses on providing healthcare data, in May announced a merger with holding company Nakamoto. Nakamoto is a holding company co-founded by Bitcoin Magazine CEO David Bailey with the intent of purchasing Bitcoin. Bailey advised President Donald Trump on crypto policy while the Republican candidate was campaigning last year. KindlyMD said on Monday that it had closed a $200 million convertible note offering as part of its Bitcoin-buying strategy. It raised another $540 million in August via a private placement in public equity (PIPE) to buy the cryptocurrency. The move is straight out of Strategy's playbook: Raise cash to buy Bitcoin so investors can buy shares of a publicly traded company and get regulated exposure to the asset. Strategy shifted from software development to focus on Bitcoin accumulation in 2020. It is the largest corporate holder of the asset with 629,376 BTC worth over $71 billion. Some 168 public companies now have Bitcoin treasuries, according to holding a total of more than 983,000 Bitcoin. Some experts have warned that the crypto play has its risks, and that pivoting to crypto won't necessarily save a failing business. But companies keep popping up, and some are amassing billions of dollars' worth of digital assets. Other notable treasuries include Twenty One, started by a combination of crypto and traditional finance powerhouses—Tether, Bitfinex, Cantor Fitzgerald, and SoftBank. It holds 43,500 BTC—almost $5 billion worth as of this writing—although it has yet to begin trading. Sign in to access your portfolio
